GO with all-day medication coverage with a straightforward nightly dosing regimen
A single bedtime dose of GOCOVRI® delivers high morning levels before the first levodopa dose and decreases in the last hours of the day1
A. An initial lag in drug release
B. Gradual increase in plasma concentrations during the night
C. High levels reached in the morning, providing all-day coverage that slowly tapers
D. Plasma concentrations decrease in the hours before bedtime
PK data do not provide evidence of clinical safety or efficacy.
There are no head-to-head studies in patients with PD comparing the safety and efficacy of GOCOVRI® to that of amantadine IR.
These simulated data are derived from a steady-state PK study using the 137 mg QHS dose of GOCOVRI® and amantadine IR 81 mg BID.1
GOCOVRI® is not interchangeable with other amantadine immediate- or extended-release products2
A convenient, single nightly dose provides all-day medication coverage2
Starting dose – week 1
Treatment dose – after week 1
Renal Considerations: A lower dose of GOCOVRI is recommended for patients with moderate to severe renal impairment.*
GOCOVRI is not contraindicated for patients with moderate to severe renal impairment. 68.5 mg is the recommended initial and maximum dosage for patients with severe renal impairment (CrCI ≥ 15-29 mL/min/1.73 m2). For patients with moderate renal impairment (CrCI ≥ 30-59 mL/min/1.73 m2), recommended initial dosage is 68.5 mg to a maximum dosage of 137 mg.*
*Please see full Prescribing Information for additional dosing information for patients with renal impairment. GOCOVRI® is contraindicated in patients with end-stage renal disease (creatinine clearance below 15 mL/min/1.73 m2).
Administration and discontinuation
If a dose is missed, the next dose should be taken as scheduled.2
GOCOVRI® can be taken with or without food. GOCOVRI® may be administered by carefully opening and sprinkling the entire content in 1 teaspoon of soft food, such as applesauce. Concomitant use of GOCOVRI® with alcohol is not recommended.2
Because rapid dose reduction or withdrawal may cause adverse reactions, it is recommended to avoid sudden discontinuation of GOCOVRI®. To avoid sudden discontinuation, patients who have taken GOCOVRI® for more than 4 weeks should reduce their dose by half during their final week of dosing.2
How can GOCOVRI support my patients?
GOCOVRI is committed to helping your patients throughout their treatment journey. See how easy it is to access and explore support offerings from GOCOVRI Onboard®.
Get clinical information on GOCOVRI
Get the latest news and updates about GOCOVRI®, learn about upcoming events, and more.